

ISLHD CANCER CLINICAL TRIALS



Illawarra Cancer Care Centre

January 2024

ISLHD CANCER CLINICAL TRIALS UNIT

**Illawarra Cancer Care Centre
Wollongong Hospital**

**Loftus Street
Wollongong NSW 2500**

Ph: 02 4253 4384

Fax: 02 4222 5085

**Email: ISLHD-
CancerClinicalTrials@health.
nsw.gov.au**

The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.

Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Breast cancer
- Colorectal cancer
- Endometrial cancer
- Gastro-oesophageal cancer
- Lung cancer
- Gynaecological neoplasms
- Neuroendocrine cancer
- Oesophageal cancer
- Prostate cancer
- Skin cancer

REFERRAL OR CONSULTATION

To discuss your patient with an ISLHD Oncology Trials Clinician, please phone the Illawarra Cancer Care Centre on
02 4222 5200

ISLHD Cancer Clinical Trials

****CURRENTLY OPEN FOR RECRUITMENT****

Scan the QR Code for more information including eligibility criteria

Breast

BRCA-P: A randomised, double blind, placebo-controlled, phase 3 study to determine the preventive effect of denosumab on breast cancer in women carrying a BRCA1 germline mutation.

Dr Naher
Tia Summer-
side



EXPERT: A randomised Phase III trial of adjuvant radiation therapy versus observation following breast conserving surgery and endocrine therapy in patients with luminal A early breast cancer.

Dr Fox
Jo Boynton /
Elise Cardoso



FINER: A double-blind, placebo-controlled, randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor.

Dr Magapu
Tia Summer-
side
**Satellite site*



TUGETHER: A phase II, two-arm non-comparative, multi-centre study of tucatinib (ONT-380), pembrolizumab (MK-3475) and trastuzumab in patients with pre-treated advanced HER2-positive breast cancer. ****Opening soon****

Dr Kasherman
Tia Summer-
side



GI/Biliary

Astellas Pancreas: A phase II, open-label, randomized study to assess the efficacy and safety of zolbetuximab (IMAB362) in combination with nab-paclitaxel and gemcitabine (Nab-P + GEM) as first line treatment in subjects with claudin 18.2 (CLDN18.2) positive, metastatic pancreatic adenocarcinoma.

Prof Chantrill
Tia Summer-
side




OXTOX: Can oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study.

Prof Chantrill
Tia Summer-
side



Neo-IMPACT: A Phase 2 study to evaluate the feasibility and safety of combining modified Folfirinox (mFolfirinox) with durvalumab (MEDI4736) in patients with resectable or borderline resectable pancreatic adenocarcinoma.






Prof Chantrill
Tia Summer-
side



ISLHD Cancer Clinical Trials

CURRENTLY OPEN FOR RECRUITMENT

Scan the QR Code for more information including eligibility criteria

GU	NINJA: Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation for patients with intermediate or low-high risk prostate cancer.	Prof Miller Lucy Sutton/ Elise Cardoso	
Gynae	PARAGON-II: Phase II basket study of an ARomatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms.	Dr Kasherman Angela Muir	
Lung	MODERN-LUNG: Phase 2 Study of a moderately hypofractionated schedule of chemoradiation followed by immunotherapy for unresectable locally advanced non-small cell lung cancer.	Dr Gandhidasan Tia Summerside	
Solid Tumours	SKB264: A multicenter, open-label, phase 2, basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors.	Dr Kasherman Tia Summerside	
Skin	CPOST: A randomised, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.	A/Prof Brungs Angela Muir	

For further information regarding these trials at the Illawarra Cancer Care Centre you may also contact the dedicated trial coordinator as listed or email ISLHD-OncologyTrials@health.nsw.gov.au

Trial Coordinator	Availability	Contact details
Kim Bate (Team Leader-Oncology)	Mon-Fri	Kim.Bate@health.nsw.gov.au
Tia Summerside	Mon-Fri	02 4253 4935
Lucy Sutton	Mon-Fri	Lucy.Sutton@health.nsw.gov.au
Angela Muir	Mon-Thurs	02 4222 5229
Elise Cardoso	Mon-Thurs	Elise.Cardoso@health.nsw.gov.au
Jo Boynton	Tues-Wed	02 4222 5739